The Medicines and Healthcare products Regulatory Agency (MHRA) has approved lecanemab for use in the UK to treat early-stage Alzheimer’s disease. However, draft guidance released simultaneously by NICE, has said that the benefits of the new drug are too small to justify the costs, and therefore has not recommended it for availability on the NHS. Here, UK DRI researchers respond to the news.
Read more
The Lancet Commission on dementia prevention, intervention and care, concludes that addressing 14 modifiable risk factors, starting in childhood and continuing throughout life, could prevent or delay nearly half of dementia cases. Here, UK DRI researchers respond to the new report.
Read more
A major new research hub involving UK DRI researchers and led by UCL and the University of Cambridge, aims to harness quantum technology to improve early diagnosis and treatment of disease.
Read more
We are pleased to announce that three new Trustees will join our Board this year. Joining the nine existing Trustees, the new Board members bring a wealth of expertise that will prove invaluable to the Institute as it enters its next phase under new Director Prof Siddharthan Chandran. The three new Trustees are Emma Whitcombe (Charity Consultant), Rabia Khan (Serna Bio) and Roudie Shafie (OVID Health).
Read more
The Dementia UK Ecosystem (DUKE) brings together leaders from the UK DRI, Dementias Platform UK, the National Institute for Health Research, the pharmaceutical industry, and funders to create a cohesive community, coordinating efforts to accelerate progress in tackling dementia.
Read more
The UK DRI exists to improve the lives of people affected by dementia. By involving people who have lived experience in our research, we can ensure new treatments and technologies meet the needs of those affected.
Read more
We have a clearly defined vision at the UK DRI to develop effective therapeutics, diagnostics and technologies for people living with dementia. Alongside building our disease knowledge over the coming years, we will also make progress in translating these discoveries into the clinic.
Translation and innovation
We accelerate, innovate, deepen and broaden discovery science in dementia, with the goal of filling the huge knowledge gap in this field. We exist to bring forward the day when research benefits people living with and those at risk of dementia.
Read our science vision
Our efforts to increase the diversity of our team, ensure inclusion and promote equality of opportunity, align with our vision for the UK DRI’s Institute culture and identity as a world-leader in dementia research.
Equity, Diversity and Inclusion
We study a range of neurodegenerative disorders that cause dementia. Many of them share fundamental disease mechanisms and characteristics, and greater understanding gained in one can often benefit others. To ensure we capitalise on diverse expertise, approaches and perspectives, we have established cross-centre themes.
Research themes